Cargando…
508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could ide...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778285/ http://dx.doi.org/10.1093/ofid/ofaa439.702 |
_version_ | 1783631099822342144 |
---|---|
author | Blair, Paul W Lanteri, Charlotte Striegel, Deborah Agan, Brian Maves, Ryan C Chenoweth, Josh Larson, Derek Mende, Katrin Colombo, Rhonda Lindholm, David Ganesan, Anuradha Richard, Stephanie Colombo, Chris Madar, Cristian Huprikar, Nikhil Tribble, David Dumler, John S Burgess, Timothy Burgess, Timothy Clark, Danielle |
author_facet | Blair, Paul W Lanteri, Charlotte Striegel, Deborah Agan, Brian Maves, Ryan C Chenoweth, Josh Larson, Derek Mende, Katrin Colombo, Rhonda Lindholm, David Ganesan, Anuradha Richard, Stephanie Colombo, Chris Madar, Cristian Huprikar, Nikhil Tribble, David Dumler, John S Burgess, Timothy Burgess, Timothy Clark, Danielle |
author_sort | Blair, Paul W |
collection | PubMed |
description | BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could identify key maladaptive immune responses during COVID-19. METHODS: Samples were collected from 76 participants (41% female, mean 46.8 years of age) enrolled at five military treatment facilities between March 20, 2020 and June 17, 2020 in an ongoing prospective COVID-19 cohort. This analysis was restricted to those with positive SARS-CoV-2 (severe acute respiratory syndrome–coronavirus 2) RT-PCR testing and included hospitalized (N=29; 10 requiring an ICU stay) and non-hospitalized (N=43) participants. Severity markers (IL6, D-dimer, procalcitonin, ferritin, ICAM-1, IL5, lipocalin, RAGE, TNFR, VEGFA, IFNγ, IL1β) were measured in plasma (mg/dL) using the Ella immunoassay and natural log transformed. Univariate negative binomial regression was performed to determine relative risk of hospitalization. Using the full marker panel, we performed a Principal Component Analysis (PCA) to determine directions of maximal variance in the data. Pearson’s correlation coefficient was determined between analytes and each axis. RESULTS: Participants requiring ambulatory-, hospital-, and ICU-level care had samples collected at 44.0 (IQR: 35.0–51.0), 40.0 (13.0–51.0), and 47.5 (21.0–54.0) days, respectively. Higher unadjusted levels of IL6, D-dimer, procalcitonin, or ferritin were each associated with hospitalization (Table 1). The PCA showed a separation along axes between level of care and duration of symptoms (Fig 1). While significant correlations were noted with a number of biomarkers, PC1 most correlated with TNFR1 (r=0.88) and PC2 most correlated with IL6Ra (r=0.95). PC1 axis variation accounted for 36.5% of variance and the PC2 axis accounted for 20.0% of variance. Figure 1. Principal Component Analysis (PCA) of biomarkers by level of care and symptom duration. [Image: see text] [Image: see text] CONCLUSION: TNFR1 and IL6Ra levels correlated with differences in the proinflammatory states between hospitalized and non-hospitalized individuals including time points late in the course of illness. Further analysis of these preliminary findings is needed to evaluate for differences by stages of illness. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-7778285 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77782852021-01-07 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals Blair, Paul W Lanteri, Charlotte Striegel, Deborah Agan, Brian Maves, Ryan C Chenoweth, Josh Larson, Derek Mende, Katrin Colombo, Rhonda Lindholm, David Ganesan, Anuradha Richard, Stephanie Colombo, Chris Madar, Cristian Huprikar, Nikhil Tribble, David Dumler, John S Burgess, Timothy Burgess, Timothy Clark, Danielle Open Forum Infect Dis Poster Abstracts BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could identify key maladaptive immune responses during COVID-19. METHODS: Samples were collected from 76 participants (41% female, mean 46.8 years of age) enrolled at five military treatment facilities between March 20, 2020 and June 17, 2020 in an ongoing prospective COVID-19 cohort. This analysis was restricted to those with positive SARS-CoV-2 (severe acute respiratory syndrome–coronavirus 2) RT-PCR testing and included hospitalized (N=29; 10 requiring an ICU stay) and non-hospitalized (N=43) participants. Severity markers (IL6, D-dimer, procalcitonin, ferritin, ICAM-1, IL5, lipocalin, RAGE, TNFR, VEGFA, IFNγ, IL1β) were measured in plasma (mg/dL) using the Ella immunoassay and natural log transformed. Univariate negative binomial regression was performed to determine relative risk of hospitalization. Using the full marker panel, we performed a Principal Component Analysis (PCA) to determine directions of maximal variance in the data. Pearson’s correlation coefficient was determined between analytes and each axis. RESULTS: Participants requiring ambulatory-, hospital-, and ICU-level care had samples collected at 44.0 (IQR: 35.0–51.0), 40.0 (13.0–51.0), and 47.5 (21.0–54.0) days, respectively. Higher unadjusted levels of IL6, D-dimer, procalcitonin, or ferritin were each associated with hospitalization (Table 1). The PCA showed a separation along axes between level of care and duration of symptoms (Fig 1). While significant correlations were noted with a number of biomarkers, PC1 most correlated with TNFR1 (r=0.88) and PC2 most correlated with IL6Ra (r=0.95). PC1 axis variation accounted for 36.5% of variance and the PC2 axis accounted for 20.0% of variance. Figure 1. Principal Component Analysis (PCA) of biomarkers by level of care and symptom duration. [Image: see text] [Image: see text] CONCLUSION: TNFR1 and IL6Ra levels correlated with differences in the proinflammatory states between hospitalized and non-hospitalized individuals including time points late in the course of illness. Further analysis of these preliminary findings is needed to evaluate for differences by stages of illness. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7778285/ http://dx.doi.org/10.1093/ofid/ofaa439.702 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Blair, Paul W Lanteri, Charlotte Striegel, Deborah Agan, Brian Maves, Ryan C Chenoweth, Josh Larson, Derek Mende, Katrin Colombo, Rhonda Lindholm, David Ganesan, Anuradha Richard, Stephanie Colombo, Chris Madar, Cristian Huprikar, Nikhil Tribble, David Dumler, John S Burgess, Timothy Burgess, Timothy Clark, Danielle 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title | 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title_full | 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title_fullStr | 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title_full_unstemmed | 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title_short | 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals |
title_sort | 508. biomarker elevation during covid-19: differences between ambulatory and hospitalized individuals |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778285/ http://dx.doi.org/10.1093/ofid/ofaa439.702 |
work_keys_str_mv | AT blairpaulw 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT lantericharlotte 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT striegeldeborah 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT aganbrian 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT mavesryanc 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT chenowethjosh 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT larsonderek 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT mendekatrin 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT colomborhonda 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT lindholmdavid 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT ganesananuradha 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT richardstephanie 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT colombochris 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT madarcristian 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT huprikarnikhil 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT tribbledavid 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT dumlerjohns 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT burgesstimothy 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT burgesstimothy 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals AT clarkdanielle 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals |